

# **Evidence on the Carcinogenicity of N-Nitrosohexamethyleneimine**

**Carcinogen Identification Committee  
November 1<sup>st</sup>, 2018**


**Jennifer C.Y. Hsieh, Kate Li, Elizabeth Marder, Gwendolyn Osborne,  
Rose Schmitz, Rajpal S. Tomar, Feng C. Tsai**

**Cancer Toxicology and Epidemiology Section  
Reproductive and Cancer Hazard Assessment Branch  
Office of Environmental Health Hazard Assessment  
CalEPA**



# N-Nitrosohexymethyleneimine (NHEX)

- Heterocyclic nitrosamine formed by a secondary amine and a nitrosating agent
- Uses: industrial process or an explosive in ejector seats of military fighter jets
- Reviews by other entities
  - European Chemicals Agency (ECHA):  
1B carcinogen



# Carcinogenicity Studies

- **Human: None**
- **Animal: 33 bioassays**

| Species | Routes of administration | Strains | Experiments |
|---------|--------------------------|---------|-------------|
| Mouse   | 2                        | 8       | 15          |
| Rat     | 2                        | 4       | 7           |
| Hamster | 2                        | 1       | 11          |



# Overview of mouse bioassays (N = 15)

| Strain  | Route:<br>No. of study (No. of strain)  | Tumor findings ( <b>rare</b> ; *statistically significant)  |
|---|---|---|
| NZO<br>NZB<br>NZC<br>NZY<br>BALB/c<br>CD-1<br>SENCAR<br>Swiss | <ul style="list-style-type: none"> <li>▪ Drinking water:<br/>10 studies (4 strains)</li> <li>▪ Gavage:<br/>3 studies (3 strains)</li> <li>▪ Subcutaneous injection:<br/>2 studies (1 strain)</li> </ul> | <p><b>nasal cavity</b> (F)</p> <p><b>oropharynx</b> (M*, F*)</p> <p><b>esophagus</b> (M*, F*)</p> <p>lung (M*, F*)</p> <p>hepatocellular adenoma/carcinoma (M*, F*)</p> <p>liver hemangioma/hemangiosarcoma (M*, F*)</p> <p><b>liver cholangioma/cholangiocarcinoma</b> (M*, F*)</p> <p><b>forestomach</b> (M*, F*)</p> <p><b>glandular stomach</b> (M*, F*)</p> <p>reticuloendothelial lymphoma (M*, F*)</p> |

M: male; F: female



# Male NZO mice – Drinking water (Goodall & Lijinsky 1984a, 1984b)

| Tumor site                  | Tumor type   | Tumor incidence      |          |
|-----------------------------|--|----------------------|----------|
|                             |  | Concentration (mg/L) |          |
|                             |  | 0                    | 200      |
| Oropharynx <sup>§</sup> (r) | Squamous cell papilloma and carcinoma and other tumors | 0/194                | 4/20***  |
| Esophagus (r)               | Squamous cell papilloma and carcinoma                  | 0/194                | 7/20***  |
| Liver                       | Hepatocellular carcinoma                               | 3/194                | 10/20*** |
|                             | Cholangioma (r) and cholangiocarcinoma (r)             | 0/194                | 6/20***  |
| Forestomach (r)             | Squamous cell papilloma and carcinoma                  | 0/194                | 14/20*** |
| Glandular stomach (r)       | Mostly benign, adenomatous                             | 0/194                | 2/20**   |
| Reticuloendothelium         | Lymphoma   | 10/194               | 8/20***  |

<sup>§</sup> Includes nasal cavity, tongue, larynx  
 \*\*p<0.01; \*\*\*p<0.001; r: rare tumor



# Female SENCAR mice - gavage (Strickland *et al.*, 1988)

| Tumor site       | Tumor type                  | Tumor incidence       |                      |
|------------------|-----------------------------|-----------------------|----------------------|
|                  |                             | Total Dose (mg/mouse) |                      |
|                  |                             | 0                     | 60                   |
| Nasal cavity (r) | Adenoma or mucosa-carcinoma | 0/20                  | 4/20 <sup>#</sup>    |
| Esophagus (r)    | Squamous cell papilloma     | 0/20                  | 4/20 <sup>#</sup>    |
| Lung             | Adenoma                     | NR                    | 15/20 <sup>***</sup> |
|                  | Adenocarcinoma              | NR                    | 6/20 <sup>*</sup>    |
|                  | All                         | 1/20                  | 17/20 <sup>***</sup> |
| Liver            | Hepatocellular adenoma      | NR                    | 6/20                 |
|                  | Hepatocellular carcinoma    | NR                    | 3/20                 |
|                  | Hemangiosarcoma             | NR                    | 3/20                 |
|                  | Cholangioma (r)             | NR                    | 3/20                 |
|                  | All                         | 3/20                  | 12/20 <sup>**</sup>  |
| Forestomach      | Squamous cell papilloma     | NR                    | 1/20                 |
|                  | Squamous cell carcinoma (r) | NR                    | 9/20 <sup>**</sup>   |
|                  | All                         | 1/20                  | 10/20 <sup>**</sup>  |

<sup>#</sup>p=0.053; \*p<0.05; \*\*p<0.01; \*\*\*p<0.001; NR: not reported; r: rare tumor



# Overview of rat bioassays (N = 6)

| Strain  | Route:<br>(No. of strain)       | Tumor findings ( <b>rare</b> ; *statistically significant)   |
|---|---------------------------------|--|
| MRC-Wistar (M, F)<br>Sprague-Dawley (M)<br>F344 (F) | Drinking<br>water:<br>3 strains | <b>nasal cavity</b> (M*, F)<br><b>tongue</b> (F)<br><b>esophagus</b> (M*, F*)<br><b>hepatocellular adenoma/carcinoma</b> (M*, F*)<br><b>liver hemangioma/hemangiosarcomas</b> (M*, F*) |

**M: male; F: female**

Note: One study included concurrent controls; 1 study used colony controls; 4 studies without controls but showed high incidences of rare tumors (*e.g.*, rare liver tumors in treated M (15/15) & F (11/15) in Goodall *et al.*, 1968)



# Male Sprague Dawley rats - drinking water (Lijinsky and Taylor, 1979)

| Tumor site          | Tumor type                       | Tumor incidence      |         |
|---------------------|----------------------------------|----------------------|---------|
|                     |                                  | Concentration (mg/L) |         |
|                     |                                  | 0#                   | 110     |
| Nasal turbinate (r) | Adenocarcinoma                   | 0/26                 | 7/15*** |
| Esophagus (r)       | Papilloma                        | 0/26                 | 9/15*** |
|                     | Carcinoma                        | 0/26                 | 2/15    |
| Liver (r)           | Hepatocellular carcinoma         | 0/26                 | 3/15*   |
|                     | Sarcoma (mostly hemangiosarcoma) | 0/26                 | 5/15**  |

#: Colony controls;

\*p<0.05; \*\*p<0.01; \*\*\*p<0.001; r: rare tumor





# Female F344 rats - drinking water (Lijinsky & Reuber, 1981)

| Tumor site    | Tumor type               | Tumor incidence      |                       |
|---------------|--------------------------|----------------------|-----------------------|
|               |                          | Concentration (mg/L) |                       |
|               |                          | 0                    | 112                   |
| Esophagus (r) | Papilloma                | 0/20                 | 4/20                  |
|               | Carcinoma                | 0/20                 | 14/20***              |
|               | Combined                 | 0/20                 | 18/20***              |
| Liver (r)     | Hepatocellular carcinoma | 1/20                 | <sup>a</sup> 6/20*    |
|               | Hemangiosarcoma          | 0/20                 | <sup>a</sup> 13/20*** |

\*p<0.05; \*\*\*p<0.001; r: rare tumor

<sup>a</sup> Three rats have both hepatocellular carcinomas and hemangiosarcomas



# Overview of hamster bioassays (N = 11)

| Strain        | Route:<br>(No. of study)              | Tumor findings ( <b>rare</b> ; *statistically significant)  |   |
|---------------|---------------------------------------|---|---|
| Syrian golden | s.c. injection:<br>7 studies          | <b>nasal cavity</b> (M*, F*)<br><b>larynx</b> (M, F)<br><b>trachea</b> (M*, F*)<br><b>lung</b> (M*) |   |
|               | Transplacental exposure:<br>4 studies | Single injection<br>(10 mg/kg)  | No treatment-related tumors                                     |
|               |                                       | Multiple-injection<br>(20-80 mg/kg)   | <b>larynx</b> (M/F combined*)<br><b>trachea</b> (M/F combined*) |

M: male; F: female



# Male Syrian hamsters - s.c. (Althoff *et al.*, 1973)

| Tumor site       | Tumor type   | Tumor incidence     |       |          |          |          |          |
|------------------|--|---------------------|-------|----------|----------|----------|----------|
|                  |  | Dose (mg/kg-bw)     |       |          |          |          |          |
|                  |  | 0                   | 4     | 8        | 16       | 32       | 64       |
| Nasal cavity (r) | Primarily adenocarcinoma                           | 0/20                | 0/19  | 1/19     | 4/19*    | 10/15*** | 0/20     |
| Larynx (r)       | Papillomas, other                                  | 0/20                | 0/19  | 2/19     | 2/19     | 2/15     | 0/20     |
| Trachea (r)      | Papillary tumors                                   | 0/20 <sup>t++</sup> | 4/19* | 12/19*** | 13/19*** | 14/15*** | 10/20*** |
| Lung-bronchi (r) | Papillary tumors, adenocarcinoma, other carcinomas | 0/20                | 2/19  | 4/19*    | 1/19     | 0/15     | 0/20     |
| Forestomach      | Squamous cell papilloma                            | 1/20                | 2/19  | 3/19     | 1/19     | 2/15     | 0/20     |

\*p<0.05; \*\*\*p<0.001

t++: Trend test p<0.01; r: rare tumor



# Pregnant female Syrian hamsters - s.c. (Althoff *et al.*, 1976)

| Tumor site       | Tumor type                            | Tumor incidence       |                          |                                  |
|------------------|---------------------------------------|-----------------------|--------------------------|----------------------------------|
|                  |                                       | Total Dose (mg/kg-bw) |                          |                                  |
|                  |                                       | 0                     | 10<br>(Single injection) | 20 - 80<br>(Multiple injections) |
| Nasal cavity (r) | Respiratory epithelium adenocarcinoma | 0/20                  | 0/40                     | 2/35                             |
| Larynx (r)       | Papillary polyps                      | 0/20                  | 0/40                     | 7/35*                            |
| Trachea (r)      | Papillary polyps                      | 0/20                  | 0/40                     | 10/35**                          |

\*p<0.05; \*\*p<0.01; r: rare tumor



# Pharmacokinetics and metabolism

- Rapidly absorbed, distributed, and completely metabolized
- Excreted in the urine and as expired CO<sub>2</sub>
- Can be metabolized by CYPs to form a number of metabolites:
  - 18 identified metabolites, *e.g.* α-, β-, γ- hydroxylated NHEX, 1,6-hexanediol, hexamethyleneimine
  - 7 proposed metabolites, *e.g.* diazohydroxide, 6-aminohexanal
  - Some unknown metabolites



# Overview of NHEX Metabolism





# Genotoxicity Studies of NHEX

| <i>Bacteria</i>  |                                       |         |       |
|--|---------------------------------------|---------|-------|
| Endpoint   | Strain                                | Results |       |
|  |                                       | - S-9   | + S-9 |
| <i>S. typhimurium</i><br>reverse mutation                    | TA1535                                | -       | +     |
|  | not specified                         | (+)     | +     |
| <i>E. coli</i> reverse mutation                              | WU 3610 ( <i>tyr-</i> , <i>leu-</i> ) | -       | +     |
| <i>In Vitro</i>  |                                       |         |       |
| Endpoint   | Target                                | Results |       |
| 6-Thioguanine or ouabain<br>resistance mutation              | Chinese hamster V79 cells             | +       |       |
| <i>In Vivo</i>   |                                       |         |       |
| <i>D. melanogaster</i> X-linked<br>recessive-lethal mutation | F <sub>2</sub> generation             | +       |       |
| RNA binding in rats  | liver                                 | +       |       |
| DNA binding in rats  |                                       | +       |       |
| DNA damage in rats   | liver, lung, kidney, duodenum         | -       |       |

+ : positive

- : negative

(+) : weakly  
positive






# Genotoxicity Studies of NHEX Metabolites

- $\beta$ -Hydroxy NHEX and  $\gamma$ -hydroxy NHEX induced base-pair substitution mutations in *S. typhimurium*.
- 1,6-Hexanediol covalently bound to liver DNA/RNA in rats *in vivo*.
- $\epsilon$ -Caprolactam: mixed, primarily negative in a wide range of assays
- Adipic acid: negative in mutagenicity assays




# Structure Activity Considerations


**2,6-Dimethylnitrosomorpholine (DMNM)**



**NHEX**




**N-Nitrosoheptamethyleneimine (NHMI)**




**Nitrosomorpholine (NM)**

P65, IARC, NTP




**N-Nitrosopiperidine (NP)**

P65, IARC, NTP



**N-Nitrosopyrrolidine (NPYR)**

P65, IARC, NTP



# Structure Activity Considerations: Tumor Sites in Animals

| Chemical | Nasal cavity | Larynx and/or trachea | Esophagus | Lung  | Liver | Fore-stomach |
|----------|--------------|-----------------------|-----------|-------|-------|--------------|
| NHEX     | R M H        | H                     | R M       | R M H | R M   | R M H        |
| DMNM     | R H          | R H                   | R H       | R H   | R H   | R H          |
| NHMI     | R H          | R H                   | R H       | R H   |       | H            |
| NM       | R H          | R H                   | R         | M     | R M   | H            |
| NP       | R H          | H                     | R H       | M H   | R M H | M H          |
| NPYR     | H            | H                     |           | M     | R     |              |

R: rat M: mouse H: hamster



# Structure Activity Considerations: Genotoxicity

| Chemical | Mutagenicity in bacteria |                | <i>In vitro</i> genotoxicity (mammalian cells) |                                | <i>In vivo</i> genotoxicity  |                 |
|----------|--------------------------|----------------|--|--------------------------------|--|-----------------|
|          | <i>S. typhimurium</i>    | <i>E. coli</i> | Mutation                                       | DNA/chromosomal damage/binding | X-linked recessive-lethal mutation assay in <i>D. melanogaster</i> | DNA/RNA binding |
| NHEX     | +                        | +              | +  | NT                             | +  | +               |
| DMNM     | +                        | NT             | NT   | +                              | +  | +               |
| NHMI     | +                        | +              | NT   | +                              | NT   | NT              |
| NM       | +                        | +              | +  | +                              | +  | +               |
| NP       | +                        | +              | +  | +                              | +  | NT              |
| NPYR     | +                        | +              | +  | +                              | +  | +               |



NT: Not tested

# QSAR Predictions for NHEX (ECHA, 2018)

## Predicted carcinogen

- QSAR Toolbox
- VEGA QSAR platform
  - CAESAR model
  - ISS model

## Predicted mutagen

- QSAR Toolbox
- VEGA QSAR platform
  - CAESAR model
  - ISS model
  - SarPy model
  - KNN model



# IARC's Key Characteristics of Carcinogens<sup>1</sup>

| Key Characteristic  | Relevant evidence for NHEX   |
|---|--|
| <b>1. Is electrophilic or can be metabolically activated</b>  | <p>Forms electrophilic metabolites</p> <ul style="list-style-type: none"> <li>• 1,6-hexanediol</li> <li>• NHEX radical</li> <li>• NHEX imminium ion</li> <li>• Carbonium ion metabolite</li> <li>• NO<sup>+</sup></li> </ul> |
| <b>2. Is genotoxic</b>  | Mutagenicity in bacteria, mammalian cells <i>in vitro</i> , and <i>Drosophila</i> ; DNA and RNA binding <i>in vivo</i>   |
| 3. Alters DNA repair or causes genomic instability            |  |
| 4. Induces epigenetic alterations                             |  |
| 5. Induces oxidative stress                                   |  |
| 6. Induces chronic inflammation                               |  |
| 7. Is immunosuppressive                                       |  |
| 8. Modulates receptor-mediated effects                        |  |
| 9. Causes immortalization                                     |  |
| 10. Alters cell proliferation, cell death, or nutrient supply |  |



<sup>1</sup>Smith et al. (2016) *Environ Health Perspect.* 2016 Jun; 124(6): 713–721.

# Summary: Animal Studies

Tumors observed in multiple species, strains and often both sexes.

| Tumor site                             | Mice   | Rats   | Hamsters |
|--|--------|--------|----------|
| Nasal cavity                           | F      | M*, F  | M*, F*   |
| Lung                                   | M*, F* | M      | M*, F    |
| Forestomach                            | M*, F* | M, F   |          |
| Esophagus                              | M*, F* | M*, F* |          |
| Glandular stomach                      | M*, F* | F      |          |
| Liver hepatocellular adenoma/carcinoma | M*, F* | M*, F* |          |
| Liver hemangioma/hemangiosarcoma       | M*, F* | M*, F* |          |
| Liver cholangioma/cholangiocarcinoma   | M*, F* |        |          |
| Oropharynx                             | M*, F* |        |          |
| Reticuloendothelium system             | M*, F* |        |          |
| Tongue                                 |        | M, F   |          |
| Larynx                                 |        |        | M, F     |
| Trachea                                |        |        | M*, F*   |

: Rare tumor sites  
 \*: Sign't increase by pairwise comparison  
**M**: Male  
**F**: Female



# Summary: Other relevant data

- NHEX is bioactivated by CYPs to form several electrophilic and/or genotoxic metabolites:
  - $\beta$ - and  $\gamma$ -Hydroxy NHEX induce mutations in *Salmonella*
  - 1,6-Hexanediol alkylates liver RNA and DNA in rats
  - Several proposed electrophilic metabolites, *e.g.*  $\text{NO}^+$ , carbonium ion metabolite, NHEX radical, NHEX iminium ion
- Genotoxicity evidence for NHEX:
  - Mutagenic in *Salmonella* and *E. coli*, in Chinese hamster V79 cells *in vitro* and in *Drosophila in vivo*
  - Covalent binding to RNA and DNA in liver of NHEX-treated rats *in vivo*





## Summary: Other relevant data (cont'd)

- Strong structure-activity similarities between NHEX and five comparison nitrosamines (four are Proposition 65 carcinogens).
  - Several QSAR models predict that NHEX is both mutagenic and carcinogenic.
- Mechanistic findings for NHEX are associated with two key characteristics of carcinogens:
  - Is electrophile or can form electrophilic metabolites
  - Is genotoxic

